OR WAIT null SECS
July 22, 2021
Kadmon Pharmaceuticals selects Onco360 to be a specialty pharmacy partner for Rezurock (belumosudil).
The companies collaborate to develop and commercialize ARV-471, an investigational oral PROTAC (proteolysis targeting chimeras) estrogen receptor protein degrader.
J&J to contribute up to $5 billion to the settlement agreement to resolve opioid-related claims and litigation in the United States.
Aenova has announced plans to open a new new can and bottle filling production line in Cornu, Romania.
Summa Equity has acquired a majority stake in G-CON Manufacturing, a prefabricated cleanroom provider.
Pfizer Inc. and BioNTech SE announced the signing of a letter of intent with The Biovac Institute Ltd to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within the African Union.
Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.
Sinovac Biotech’s Eupolio vaccine, a Sabin inactivated poliovirus vaccine (sIPV), has gained marketing authorization in China.
Exscientia and GT Apeiron Therapeutics have entered into a strategic R&D oncology collaboration agreement.
Specialty pharmaceutical company, Advanz Pharma, has launched a generic version of lanreotide, MYTOLAC, in Germany.